Quantcast

Latest Cancer treatments Stories

2014-06-10 16:26:49

SCHAUMBURG, Ill., June 10, 2014 /PRNewswire-USNewswire/ -- Extensive clinical experience suggests that hyperthermic intraperitoneal chemotherapy (HIPEC) may play an important role in the ongoing treatment of colorectal cancer patients with peritoneal carcinomatosis (CRCPC). However, there is no established nonsurgical process to select patients for HIPEC treatment as part of recommended standard of care or for clinical trial inclusion....

2014-06-10 04:22:14

Inovio Targets Most Rapidly Increasing Cancer in Men BLUE BELL, Pa., June 10, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity and clinical responses of its immunotherapy product, INO-3112, in treating human papillomavirus (HPV)- associated head and neck cancer. INO-3112 is a combination of Inovio's lead active immunotherapy product, VGX-3100, and its proprietary immune...

2014-06-09 12:31:07

TSX Venture: QPT EDMONTON, June 9, 2014 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, reports today that patient enrollment has been completed in the Company's Phase IIb clinical trial of its lead immunotherapy product candidate Oregovomab for the treatment of Ovarian Cancer. "I am pleased that we have reached this important milestone in our clinical program"...

2014-06-03 15:54:17

Rice University Animal tests show Rice-developed technology effective against aggressive cancer The first preclinical study of a new Rice University-developed anti-cancer technology found that a novel combination of existing clinical treatments can instantaneously detect and kill only cancer cells -- often by blowing them apart -- without harming surrounding normal organs. The research, which is available online this week Nature Medicine, reports that Rice's "quadrapeutics" technology...

2014-06-03 11:48:40

University of Colorado Denver At the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO), University of Colorado Cancer Center researchers reported results of a Phase I trial of OMP-54F28 (FZD8-Fc), an investigational drug candidate discovered by OncoMed Pharmaceuticals targeting cancer stem cells (CSCs). The drug was generally well tolerated, and several of the 26 patients with advanced solid tumors experienced stable disease for greater than six months. Three trials...

2014-06-02 08:30:18

SEATTLE, June 2, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today announced the presentation of data from a Phase 1 trial of ONT-10, an antigen-specific immunotherapy targeting MUC1, at the American Association of Clinical Oncology (ASCO) 2014 Annual Meeting in Chicago. The data demonstrated that ONT-10 was well tolerated in this trial, resulted in a humoral immune response in the majority of patients and led to encouraging disease control in advanced stage patients with...

2014-06-01 08:20:43

New Study Shows Oncotype DX® DCIS Score(TM) Changes Treatment Recommendations for One Out of Three DCIS Patients REDWOOD CITY, Calif., June 1, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results of six studies being presented at the 2014 American Society of Clinical Oncology(®) (ASCO(®)) Annual Meeting taking place May 30 - June 3 in Chicago, underscoring the practice-changing value of Oncotype DX(®)( )in pre-invasive and invasive breast cancer and colon...

2014-06-01 08:20:41

NEW YORK, June 1, 2014 /PRNewswire/ -- The Cancer Research Institute (CRI) is proud to announce the launch of a first-of-its-kind website devoted to cancer immunotherapy, also called immuno-oncology, designed specifically for cancer patients and their caregivers, TheAnswerToCancer.org. http://photos.prnewswire.com/prnvar/20140530/92827 "As major advances in cancer immunotherapy begin to alter the landscape of cancer treatment, patients facing a cancer diagnosis need to be aware of...

2014-05-31 08:21:17

Data Support Adoption of Stable Disease as Response Criterion, Raise Intriguing Hypotheses about Sequential Therapy and Utility of IL-2 as Salvage Option CHICAGO, May 31, 2014 /PRNewswire/ -- Prometheus Laboratories Inc. announced today that data from the PROCLAIM(SM) national patient registry retrospective cohort document an improvement in median overall survival (OS) in patients with metastatic melanoma who were treated with high-dose Proleukin(®) (aldesleukin) as compared to...

2014-05-30 08:25:14

Retrospective Analysis Demonstrates Survival Benefits for Patients with Stable and Progressive Disease after HD IL-2 in the Modern Era Suggesting Appropriate Drug Sequencing May Improve Outcomes CHICAGO, May 30, 2014 /PRNewswire/ -- Prometheus Laboratories Inc. announced today that analysis of data from the PROCLAIM(SM) national patient registry retrospective cohort shows improved overall survival in metastatic RCC patients treated with high-dose Proleukin(®) (aldesleukin) in the...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.